{"id":200450,"date":"2025-09-30T00:00:00","date_gmt":"2025-09-30T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/47041183-medtech-urological-devices-market-insights-europe\/"},"modified":"2026-05-03T23:01:28","modified_gmt":"2026-05-03T23:01:28","slug":"47042559-medtech-urological-devices-market-insights-europe","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/47042559-medtech-urological-devices-market-insights-europe\/","title":{"rendered":"Urological Devices &#8211; Market Insights &#8211; Europe"},"content":{"rendered":"<p>The European urological device market is set to grow through 2034, driven by product innovation, rising awareness, increasing kidney stone cases, and an aging population. Growth will be led by <abbr title=\"Benign Prostatic Hyperplasia\">BPH<\/abbr> devices\u2014especially Aquablation, and <abbr title=\"Urinary Incontinence\">UI<\/abbr> devices. Additional market drivers include rising obesity rates, premium device adoption, and broader access to less-invasive treatments. However, reimbursement challenges, litigation risks tied to genitourinary meshes, and healthcare budget constraints will limit uptake of newer, premium-priced technologies.<\/p>\n<p>This Medtech 360 Report provides comprehensive data and analysis on the of the market for urological devices in Europe from 2019 through 2034.<\/p>\n<p><strong>Ongoing clinical studies and research continue to affect procedure trends, and thus device adoption trends.<\/strong><\/p>\n<p>What do recent studies indicate regarding the outlook of existing techniques for treating prostate cancer and <abbr title=\"Benign Prostatic Hyperplasia\">BPH<\/abbr>?<\/p>\n<p>What upcoming novel treatments are expected to compete with existing methods of treatment?<\/p>\n<p class=\"question-statement\"><b>Mergers and acquisitions have been altering the competitive landscape.<\/b><\/p>\n<p>What are the most relevant recent acquisitions affecting the market?<\/p>\n<p>How will market shares and product portfolios be affected as a result of these acquisitions?<\/p>\n<p class=\"question-statement\"><strong>Minimally invasive treatment volumes will increase in Europe over the forecast period.<\/strong><\/p>\n<p>What factors contribute to the increase of minimally invasive treatments?<\/p>\n<p>How have minimally invasive treatment options changed the <abbr title=\"Benign Prostatic Hyperplasia\">BPH<\/abbr> device market?<\/p>\n<p>Which market segments will see the greatest adoption of minimally invasive treatments?<\/p>\n<p>What is the impact of Aquablation on the Europe urological device market?<\/p>\n<p class=\"question-statement\"><strong><abbr title=\"Urinary Incontinence\">UI<\/abbr> device segment represents a significant proportion of the overall market revenues.<\/strong><\/p>\n<p>What factors impact the use of <abbr title=\"Urinary Incontinence\">UI<\/abbr> devices?<\/p>\n<p>How will the change in <abbr title=\"Average Selling Price\">ASP<\/abbr>s of <abbr title=\"Urinary Incontinence\">UI<\/abbr> devices affect the market?<\/p>\n<p><strong>Premium devices and their adoption will influence market trends.<\/strong><\/p>\n<p>Which device markets are going to be affected by preference for premium variants of devices?<\/p>\n<p>What circumstances hinder the uptake of premium devices in the European region?<\/p>\n<p class=\"question-statement\"><b>Some market segments are being negatively impacted by product safety concerns<\/b><strong>.<\/strong><\/p>\n<p>Which market segments are being impacted by safety concerns?<\/p>\n","protected":false},"template":"","class_list":["post-200450","report","type-report","status-publish","hentry","report-gateway-medtech","medtech-therapy-area-urological-devices","medtech-therapy-area-urology","medtech-geography-europe","medtech-date-2294"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/200450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":4,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/200450\/revisions"}],"predecessor-version":[{"id":540350,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/200450\/revisions\/540350"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=200450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}